{"id":12497,"date":"2024-10-11T20:35:33","date_gmt":"2024-10-11T18:35:33","guid":{"rendered":"https:\/\/valintermed.com\/?p=12497"},"modified":"2024-10-11T20:35:33","modified_gmt":"2024-10-11T18:35:33","slug":"pankreaticheskaya-protokovaya-adenokartsinoma","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/pancreatic-ductal-adenocarthritis\/","title":{"rendered":"Pancreatic ductal adenocarcinoma"},"content":{"rendered":"
<\/div>\n

Pancreatic ductal adenocarcinoma (PDA) is a malignant neoplasm derived from the cells of the pancreatic ductal system. This form of cancer is characterized by an aggressive course and high mortality, which is due to both late diagnosis and the complexity of surgical intervention on the pancreas. PDA accounts for about 85% of all pancreatic cancer cases and is usually diagnosed at late stages, which limits the possibilities of effective treatment. Clinically, the disease manifests itself with nonspecific symptoms such as loss of appetite, weight loss, abdominal pain and jaundice. Given its high invasiveness and metastatic potential, PDA requires a multidisciplinary approach to diagnosis and treatment.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n